Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir.
2024

AURORA: A New Dawn

publication Evidence: moderate

Author Information

Author(s): Papanicolaou Genovefa A, Avery Robin K, Cordonnier Catherine, Duarte Rafael F, Haider Shariq, Maertens Johan, Peggs Karl S, Solano Carlos, Young Jo-Anne H, Fournier Martha, Murray Rose Ann, Wu Jingyang, Bo Tien, Winston Drew J

Primary Institution: Takeda Development Center Americas, Inc

Hypothesis

AURORA was the first randomized, double-blind study to compare 2 oral antiviral agents with a primary end point of cytomegalovirus (CMV) clearance.

Conclusion

AURORA confirmed the anti-CMV activity of maribavir with less neutropenia compared with valganciclovir for CMV infection after hematopoietic stem cell transplant.

Supporting Evidence

  • Comparable viremia clearance was achieved during 8 weeks of treatment (maribavir: 83%; valganciclovir: 86%).
  • Patients had fewer treatment-emergent adverse events (TEAEs), hospitalizations, and TEAE-related discontinuations with maribavir than with valganciclovir.
  • More recurrent CMV infections occurred after the 8-week treatment period with valganciclovir (23% vs 19%).
  • Maribavir's efficacy and safety profile enables its use among patients at risk of intolerances.

Takeaway

This study looked at two medicines to help people with a virus called CMV after a transplant. One medicine worked better and caused fewer side effects.

Methodology

Randomized, double-blind study comparing maribavir and valganciclovir.

Potential Biases

Potential bias due to the study design and strict entry criteria.

Limitations

The study had an 8-week treatment period and included high-risk patients with a lower viral load than originally planned.

Participant Demographics

18% of the study population were high-risk patients with a viral load >455 IU/mL.

Digital Object Identifier (DOI)

10.1093/cid/ciae114

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication